News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Humanetics Receives Orphan Drug Designation for Its BIO 300 Radiation Countermeasure


7/20/2007 11:08:24 AM

MINNEAPOLIS--(BUSINESS WIRE)--Humanetics Corporation, a privately held pharmaceutical company, today announced that the United States Food and Drug Administration (FDA) has granted orphan drug designation to its BIO 300 investigational drug for the prevention of Acute Radiation Syndrome (ARS). BIO 300 is being developed as a medical countermeasure for ionizing radiation resulting from a nuclear or radiological attack, act of terrorism or accident. It is the first and, to date, only drug to receive orphan designation for the prevention of ARS.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES